Search Results

FDA Approves Next Generation MicroPort CRM Alizea TM and Celea TM Pacemaker Systems.

Shanghai MicroPort MedBot (Group) Co., Ltd. (“MicroPort MedBot”) announced that on November 22nd, 2022 MicroPort NaviBot International, LLC in recent collaboration with MicroPort Orthopedics has completed the first clinical use of the SkyWalker™ Robotic System in the United States.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces that registration is open for its second annual Global Medial-Pivot Symposium in Phoenix, Arizona from October 13-14, 2023.

MicroPort Orthopedics is a medical device company specializing in large joint replacements with clinical data/history dating back over 20 years.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces the expansion of its partnership with Pixee Medical through the commercialization of its combined surgical solution in the United States.

MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic valve implantation (TAVI) device, the VitaFlow LibertyTM Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow LibertyTM), has received EU CE-MDR certification.

MicroPort Navibot has received 510(K) clearance from the Food and Drug Administration (FDA) in the United States for the SkyWalker™ System, the company’s first robot-assisted platform for orthopedic applications.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces the expansion of its commercial leadership team with two strategic hires: Brian Collins is joining as Global Vice President of Marketing and Professional Education and Shawn Gabriel as Vice President of Sales, North America.

MicroPort CRM, a subsidiary of MicroPort Scientific Corporation, a pioneering company in the field of Cardiac Rhythm Management, has launched an online education website, MicroPort Academy CRM.